Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07360457

GLP1 Analogues and the Risk of Osteoarthritis

Association of GLP1 Analogues and SGLT2 Inhibitors With the Risk of Osteoarthritis in Type 2 Diabetic Patients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
390 (estimated)
Sponsor
Beni-Suef University · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.

Detailed description

Osteoarthritis (OA) is a multifactorial joint disease related to multiple inflammatory pathways which are triggered by mechanical and cellular stress, leading to increased production of pro-inflammatory mediators, reactive oxygen species, advanced glycation end products (AGEs). These mediators promote the release of proteolytic enzymes, which degrade the cartilage matrix. A recent study emphasized on the relation between metabolic syndrome and OA, considering metabolic dysregulation as a major factor in OA progression. GLP-1 receptor agonists lower blood sugar by boosting glucose-dependent insulin release, reducing glucagon secretion, and slowing stomach emptying. GLP-1RA is present in both healthy and osteoarthritic cartilage, indicating a direct effect on chondrocytes. so it can decrease the accumulation of AGEs, which is the main cause of OA. It also reduces appetite, leading to weight loss which decreases the mechanical stress on joints. GLP downregulates proinflammatory cytokines (IL-6, TNF-a). also inhibits NF-κB pathway. which has a role in promoting osteoclast formation, so GLP plays a protective role in OA.

Conditions

Interventions

TypeNameDescription
DRUGGLP-1 analogglucagon like peptide analogues
DRUGSGLT2 inhibitorsodium glucose transporter-2 inhibitors
DRUGAntidiabeticStandard of care

Timeline

Start date
2026-02-01
Primary completion
2026-12-01
Completion
2027-03-01
First posted
2026-01-22
Last updated
2026-01-22

Source: ClinicalTrials.gov record NCT07360457. Inclusion in this directory is not an endorsement.